Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

98.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,486
Open 98.30
Bid (Size) 97.04 (300)
Ask (Size) 97.53 (400)
Prev. Close 98.30
Today's Range 98.30 - 98.30
52wk Range 79.52 - 124.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool

Performance

YTD
+1.7%
+1.7%
1 Month
-3.3%
-3.3%
3 Month
+4.7%
+4.7%
6 Month
+9.9%
+9.9%
1 Year
-0.3%
-0.3%

More News

Read More
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
Via The Motley Fool
BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗
Via Chartmill
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
Via The Motley Fool
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
From BioNTech SE
Via GlobeNewswire
News headline image
Why Pfizer Stock Was so Healthy in August ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
Via The Motley Fool
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
From BioNTech SE
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗
Via The Motley Fool
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
From BioNTech SE
Via GlobeNewswire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Via The Motley Fool

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 98.30
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 09/30/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.